Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Health and Quality of Life Outcomes
Published in: Health and Quality of Life Outcomes 1/2014

Open Access 01-12-2014 | Research

Improvements in quality of life associated with biphasic insulin aspart 30 in type 2 diabetes patients in China: results from the A1chieve® observational study

Authors: Wenying Yang, Xiaoming Zhuang, Yukun Li, Qing Wang, Rongwen Bian, Jianguo Shen, Eva Hammerby, Li Yang

Published in: Health and Quality of Life Outcomes | Issue 1/2014

Login to get access

Abstract

Background

Based on the 24-week, prospective, non-interventional, observational study, A1chieve®, we investigated how health-related quality of life (HRQoL) changed, and the predictors of such changes, in Chinese people with type 2 diabetes mellitus (T2DM) after starting with, or switching to, biphasic insulin aspart 30 (BIAsp 30).

Methods

In total, 8,578 people with T2DM starting treatment with, or switching to, BIAsp 30 were recruited from 130 urban hospitals in China. HRQoL was assessed at baseline and 24 weeks using the EuroQol-5 dimensions (EQ-5D) questionnaire. Descriptive statistics, paired t-test, and chi-square test were conducted and the linear ordinary least squares regression model was used to determine predictors for changes in EQ-5D score.

Results

Haemoglobin A1c (HbA1c) decreased from 9.5% to 7.0% after 24 weeks. The reported HRQoL measured by the EQ-5D visual analogue scale score increased by 6.2 (p < 0.001) from 75.8 to 82.0, and EQ-5D index score increased by 0.018 (p < 0.001) from 0.875 to 0.893 for the cohort over 24 weeks. The percentage of patients reporting no problems in the mobility, pain/discomfort, and anxiety/depression dimensions of EQ-5D increased significantly (p < 0.001) from 88.4% to 91.4%, 77.3% to 82.8%, and 74.2% to 77.1%, respectively. Patients with higher HbA1c levels at baseline, major hypoglycaemia or micro-complications exhibited significantly larger changes in EQ-5D scores than those with lower baseline HbA1c levels, without major hypoglycaemia or micro-complications after controlling for demographics and other baseline characteristics.

Conclusions

BIAsp 30 treatment was associated with improved glycaemic control and HRQoL in T2DM patients in China. Patients with worse health conditions were more likely to experience larger improvements in HRQoL than those with better health conditions.

Trial registration

ClinicalTrials.gov, NCT00869908.
Appendix
Available only for authorised users
Literature
1.
2.
Xu Y, Wang L, He J, Bi Y, Li M, Wang T, Wang L, Jiang Y, Dai M, Lu J, Xu M, Li Y, Hu N, Li J, Mi S, Chen CS, Li G, Mu Y, Zhao J, Kong L, Chen J, Lai S, Wang W, Zhao W, Ning G: Prevalence and control of diabetes in Chinese adults. JAMA 2010, 2013(310):948–958.
3.
4.
Wu N, Aagren M, Boulanger L, Friedman M, Wilkey K: Assessing achievement and maintenance of glycemic control by patients initiating basal insulin. Curr Med Res Opin 2012, 28: 1647–1656. 10.1185/03007995.2012.722989CrossRefPubMed
5.
Massi-Benedetti M, Orsini-Federici M: Treatment of type 2 diabetes with combined therapy: what are the pros and cons? Diabetes Care 2008, 31(Suppl 2):S131-S135. 10.2337/dc08-s233CrossRefPubMed
6.
Pouwer F, Hermanns N: Insulin therapy and quality of life. A review. Diabetes Metab Res Rev 2009, 25(Suppl 1):S4-S10. 10.1002/dmrr.981CrossRefPubMed
7.
Funnell MM: Quality of life and insulin therapy in type 2 diabetes mellitus. Insulin 2008, 3: 31–36. 10.1016/S1557-0843(08)80009-7CrossRef
8.
Vinik AI, Zhang Q: Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes. Diabetes Care 2007, 30: 795–800. 10.2337/dc06-1712CrossRefPubMed
9.
Houlden R, Ross S, Harris S, Yale JF, Sauriol L, Gerstein HC: Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of type 2 diabetes: the Canadian INSIGHT study. Diabetes Res Clin Pract 2007, 78: 254–258. 10.1016/j.diabres.2007.03.021CrossRefPubMed
10.
Jacobson AM: Impact of improved glycemic control on quality of life in patients with diabetes. Endocr Pract 2004, 10: 502–508. 10.4158/EP.10.6.502CrossRefPubMed
11.
Redekop WK, Koopmanschap MA, Stolk RP, Rutten GE, Wolffenbuttel BH, Niessen LW: Health related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care 2002, 25: 458–463. 10.2337/diacare.25.3.458CrossRefPubMed
12.
Davis RE, Morrissey M, Peters JR, Wittrup-Jensen K, Kennedy-Martin T, Currie CJ: Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes. Curr Med Res Opin 2005, 21: 1477–1483. 10.1185/030079905X61929CrossRefPubMed
13.
Barendse S, Singh H, Frier BM, Speight J: The impact of hypoglycaemia on quality of life and related patient-reported outcomes in Type 2 diabetes: a narrative review. Diabet Med 2011, 29: 293–302. 10.1111/j.1464-5491.2011.03416.xCrossRef
14.
Shah SN, Litwak L, Haddad J, Chakkarwar PN, Hajjaji I: The A1chieve study: a 60 000-person, global, prospective, observational study of basal, meal-time, and biphasic insulin analogs in daily clinical practice. Diabetes Res Clin Pract 2010, 88(Suppl 1):S11–S16.CrossRefPubMed
15.
EuroQol Group: EuroQol-a new facility for the measurement of health-related quality of life Health Policy 1990, 16: 199–208. 10.1016/0168-8510(90)90421-9
16.
17.
Wang HM, Patrick DL, Edwards TC, Skalicky AM, Zeng HY, Gu WW: Validation of the EQ-5D in a general population sample in urban China. Qual Life Res 2012, 21: 155–160. 10.1007/s11136-011-9915-6CrossRefPubMed
18.
Sun S, Chen J, Johannesson M, Kind P, Xu L, Zhang Y, Burström K: Population health status in China: EQ-5D results, by age, sex and socio-economic status, from the national health services survey 2008. Qual Life Res 2011, 20: 309–320. 10.1007/s11136-010-9762-xPubMedCentralCrossRefPubMed
19.
Wang H, Kindig DA, Mullahy J: Variation in Chinese population health related quality of life: results from a EuroQol study in Beijing, China. Qual Life Res 2005, 14: 119–132. 10.1007/s11136-004-0612-6CrossRefPubMed
20.
Sheu WH, Ji LN, Nitiyanant W, Baik SH, Yin D, Mavros P, Chan SP: Hypoglycemia is associated with increased worry and lower quality of life among patients with type 2 diabetes treated with oral antihyperglycemic agents in the Asia-Pacific region. Diabetes Res Clin Pract 2012, 96: 141–148. 10.1016/j.diabres.2011.12.027CrossRefPubMed
21.
Li H, Wei X, Ma A, Chung RY: Inequalities in health status among rural residents: EQ-5D findings from household survey China. Int J Equity Health 2014, 13: 41–48. 10.1186/1475-9276-13-41PubMedCentralCrossRefPubMed
22.
Liang Y, Lu W, Wu W: Are social security policies for Chinese landless farmers really effective on health in the process of Chinese rapid urbanization? A study on the effect of social security policies for Chinese landless farmers on their health-related quality of life. Int J Equity Health 2014, 13: 5–20. 10.1186/1475-9276-13-5PubMedCentralCrossRefPubMed
23.
Yang W, Li Y, Chen L, Shi Y, Peng Y, Lei M: Clinical use of daily biphasic insulin aspart 30 in Chinese people with type 2 diabetes: results of A1chieve observational study. Chin J Diabetes Mellitus 2012, 4: 607–612.
24.
Shah S, Zilov A, Malek R, Soewondo P, Bech O, Litwak L: Improvements in quality of life associated with insulin analogue therapies in people with type 2 diabetes: results from the A1chieve observational study. Diabetes Res Clin Pract 2011, 94: 364–370.
25.
Moses A, Chawla R, John W: Insulin analogue therapy improves quality of life in patients with type 2 diabetes in India: the A1chieve Study. J Assoc Phys India 2013, 61(Suppl.1):31–40.
26.
Schmoelzer I, de Campo A, Pressl H, Stelzl H, Dittrich P, Oettl K: Biphasic insulin aspart compared to biphasic human insulin reduces postprandial hyperlipidemia in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2005, 113: 176–181. 10.1055/s-2005-837521CrossRefPubMed
27.
McSorley PT, Bell PM, Jacobsen LV, Kristensen A, Lindholm A: Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus. Clin Ther 2002, 24: 530–539. 10.1016/S0149-2918(02)85129-3CrossRefPubMed
28.
Tamemoto H, Ikoma A, Saitoh T, Ishikawa SE, Kawakami M: Comparison of once-daily glargine plus sulfonylurea with twice-daily 70/30 aspart premix in insulin-naive Japanese patients with diabetes. Diabetes Technol Ther 2007, 9: 246–253. 10.1089/dia.2006.0016CrossRefPubMed
29.
Kilo C, Mezitis N, Jain R, Mersey J, McGill J, Raskin P: Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications 2003, 17: 307–313. 10.1016/S1056-8727(03)00076-XCrossRefPubMed
30.
Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P: Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005, 28: 260–265. 10.2337/diacare.28.2.260CrossRefPubMed
31.
Home H, Naggar NE, Khamseh M, Gonzalez-Galvez G, Shen C, Chakkarwar P: An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: The A1chieve study. Diabetes Res Clin Pract 2011, 94: 352–363.
32.
Valensi P, Benroubi M, Borzi V: Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30⁄70 (NovoMixR 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVETM observational study. Int J Clin Pract 2009, 63: 522–531. 10.1111/j.1742-1241.2009.02002.xCrossRefPubMed
33.
Rubin RR, Peyrot M: Quality of life and diabetes. Diabetes Metab Res Rev 1999, 15: 205–218. 10.1002/(SICI)1520-7560(199905/06)15:3<205::AID-DMRR29>3.0.CO;2-OCrossRefPubMed
34.
Magwood GS, Zapka J, Jenkins CA: Review of systematic reviews evaluating diabetes interventions: focus on quality of life and disparities. Diabetes Educ 2008, 34: 242–265. 10.1177/0145721708316551PubMedCentralCrossRefPubMed
35.
Zhang X, Norris SL, Chowdhury FM, Gregg EW, Zhang P: The effects of interventions on health-related quality of life among persons with diabetes: a systematic review. Med Care 2007, 45: 820–834. 10.1097/MLR.0b013e3180618b55CrossRefPubMed
36.
Barendse S, Singh H, Frier BM, Speight J: The impact of hypoglycaemia on quality of life and related patient-reported outcomes in Type 2 diabetes: a narrative review. Diabet Med 2012, 29: 293–302. 10.1111/j.1464-5491.2011.03416.xCrossRefPubMed
Metadata
Title
Improvements in quality of life associated with biphasic insulin aspart 30 in type 2 diabetes patients in China: results from the A1chieve® observational study
Authors
Wenying Yang
Xiaoming Zhuang
Yukun Li
Qing Wang
Rongwen Bian
Jianguo Shen
Eva Hammerby
Li Yang
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2014
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-014-0137-9

Other articles of this Issue 1/2014

Health and Quality of Life Outcomes 1/2014 Go to the issue

Research

Construct and concurrent validity of a patient-reported adverse drug event questionnaire: a cross-sectional study

Research

A confirmatory bifactor analysis of the hospital anxiety and depression scale in an Italian community sample

Research

Psychometric evaluation, using Rasch analysis, of the WHOQOL-BREF in heroin-dependent people undergoing methadone maintenance treatment: further item validation

Research

Quality of life in children with OCD with and without comorbidity

Research

Comparison of the ECOHIS and short-form P-CPQ and FIS scales

Research

“Getting stuck with LAM”: patients perspectives on living with Lymphangioleiomyomatosis